158 related articles for article (PubMed ID: 25702159)
41. [The preparation of myeloma-specific T cells activated with dendritic cells loaded with nonapeptides derived from mucin protein MUC1 and catalytic subunit of telomerase hTERT].
Ocadlíková D; Kovárová L; Hájek R; Michálek J
Klin Onkol; 2008; 21(2):59-65. PubMed ID: 19102213
[TBL] [Abstract][Full Text] [Related]
42. [MUC1, a therapeutic target in oncology].
Limacher JM; Acres B
Bull Cancer; 2007 Mar; 94(3):253-7. PubMed ID: 17371767
[TBL] [Abstract][Full Text] [Related]
43. The development of synthetic antitumour vaccines from mucin glycopeptide antigens.
Gaidzik N; Westerlind U; Kunz H
Chem Soc Rev; 2013 May; 42(10):4421-42. PubMed ID: 23440054
[TBL] [Abstract][Full Text] [Related]
44. Immunization with a Synthetic Human MUC1 Glycopeptide Vaccine against Tumor-Associated MUC1 Breaks Tolerance in Human MUC1 Transgenic Mice.
Stergiou N; Glaffig M; Jonuleit H; Schmitt E; Kunz H
ChemMedChem; 2017 Sep; 12(17):1424-1428. PubMed ID: 28675699
[TBL] [Abstract][Full Text] [Related]
45. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers.
Bohnenkamp HR; Coleman J; Burchell JM; Taylor-Papadimitriou J; Noll T
Cell Immunol; 2004; 231(1-2):112-25. PubMed ID: 15919376
[TBL] [Abstract][Full Text] [Related]
46. Synthesis and Immunological Evaluation of a Single Molecular Construct MUC1 Vaccine Containing l-Rhamnose Repeating Units.
Hossain MK; Vartak A; Sucheck SJ; Wall KA
Molecules; 2020 Jul; 25(14):. PubMed ID: 32659971
[TBL] [Abstract][Full Text] [Related]
47. Breast cancer immunotherapy: current status and future prospects.
Apostolopoulos V; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1996 Oct; 74(5):457-64. PubMed ID: 8912009
[TBL] [Abstract][Full Text] [Related]
48. Mucin gene (MUC1) transfer into human dendritic cells by cationic liposomes and recombinant adenovirus.
Pecher G; Spahn G; Schirrmann T; Kulbe H; Ziegner M; Schenk JA; Sandig V
Anticancer Res; 2001; 21(4A):2591-6. PubMed ID: 11724326
[TBL] [Abstract][Full Text] [Related]
49. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
[TBL] [Abstract][Full Text] [Related]
50. Tumor regression by CD4 T-cells primed with dendritic/tumor fusion cell vaccines.
Koido S; Enomoto Y; Apostolopoulos V; Gong J
Anticancer Res; 2014 Aug; 34(8):3917-24. PubMed ID: 25075013
[TBL] [Abstract][Full Text] [Related]
51. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
Soares MM; Mehta V; Finn OJ
J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
[TBL] [Abstract][Full Text] [Related]
52. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
53. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
[TBL] [Abstract][Full Text] [Related]
54. MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.
Lakshminarayanan V; Supekar NT; Wei J; McCurry DB; Dueck AC; Kosiorek HE; Trivedi PP; Bradley JM; Madsen CS; Pathangey LB; Hoelzinger DB; Wolfert MA; Boons GJ; Cohen PA; Gendler SJ
PLoS One; 2016; 11(1):e0145920. PubMed ID: 26788922
[TBL] [Abstract][Full Text] [Related]
55. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
[TBL] [Abstract][Full Text] [Related]
56. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
[TBL] [Abstract][Full Text] [Related]
57. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas.
Akporiaye ET; Bradley-Dunlop D; Gendler SJ; Mukherjee P; Madsen CS; Hahn T; Besselsen DG; Dial SM; Cui H; Trevor K
Vaccine; 2007 Sep; 25(39-40):6965-74. PubMed ID: 17707958
[TBL] [Abstract][Full Text] [Related]
58. MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model.
Mukherjee P; Pathangey LB; Bradley JB; Tinder TL; Basu GD; Akporiaye ET; Gendler SJ
Vaccine; 2007 Feb; 25(9):1607-18. PubMed ID: 17166639
[TBL] [Abstract][Full Text] [Related]
59. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells.
Hiltbold EM; Vlad AM; Ciborowski P; Watkins SC; Finn OJ
J Immunol; 2000 Oct; 165(7):3730-41. PubMed ID: 11034378
[TBL] [Abstract][Full Text] [Related]
60. The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy.
Agrawal B; Gendler SJ; Longenecker BM
Mol Med Today; 1998 Sep; 4(9):397-403. PubMed ID: 9791863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
